Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Mad2 who wrote (227)	2/5/1999 10:13:00 PM
From: Mike M	Read Replies (2) \| Respond to of 5582

iand a price to sales of 14 and it isn't making money yet. I would venture a guess that GUMM will be lining up a private placement (terms, dilution, amount??) as they are undercapitalized. Here's a maddening idea...Pose your question to Brown Russell in the same somber way you ask it here....See if you can get his goat... Those guys know they have something special here and they won't let you dampen their spirits.... You act like nobody ever had to develop demand for a better mousetrap with little money before. What is so rich is that the little company has come so far already and the naysayers continue to chant..."can't be done"... Is this like a mantra for you guys?...All I can say is keep it up, while the company stuffs it right down your throat. Regards, Mike

To: Mad2 who wrote (227)	2/5/1999 11:01:00 PM
From: DanZ	Read Replies (1) \| Respond to of 5582

Mad2, I agree that GumTech's price to sales ratio looks high when calculated using past revenues. However, stock prices discount the future and not the past. How else can one explain the high valuations is stocks like YHOO, SEEK, AMZN, etc...? The fact that GUMM is trading at a price to book of 16 and a price to sales of 14 tells us one of two things: Either the company's sales and book value are going to increase in the future OR the stock price is overvalued and will probably decline. Dave Rich of GunnAllen analyzed GumTech's business units (without Zicam) and estimated that the company will do $24 million in sales in 1999. Let's suppose for a moment that he is right and the company does $24 million in sales. $24 million divided by 6.85 million shares outstanding is $3.50 per share in sales. At today's closing stock price of 10 5/8, GUMM is trading at a much more respectable 3 times sales. Let's also assume that the stock price appreciates to Dave's target of 24 and they do $24 million in sales. Based on these assumptions, the stock would be trading at 6.8 times sales, which is very reasonable for a company that would have grown sales from $4 million last year to $24 million this year. In fact, if the company turns $24 million in sales and earn 87 cents per share as estimated by Dave, I think the stock could trade to 27 or 30. I'm basing this on a PE of 30 to 35 times, which would not be unreasonable given the potential growth in earnings. This comes down to either you believe the estimates or you don't. Keep in mind also that the $24 million sales estimate is for the gum business only. Any sales due to Zicam would only further enhance the value of the stock. Nobody knows for sure how much the company will make from Zicam, but estimates are that GelTech will sell $45 million worth of Zicam in the first year. This is based on 3% of the $1.5 billion market for cold medications. Since GUMM owns 60% of GelTech, GumTech would book an additional $27 million in sales if GelTech sells $45 million in Zicam. That would give the company $41 million in sales, or sales per share of $5.99. Based on a price to sales ratio of 5 to 6, the stock could trade to 30 - 36 if they do $41 million in sales. We can debate the numbers for days on end. Like I said, it comes down to what you think is in this company's future. I will caution you, however, about trying to use past sales data to justify your short position. Best of luck, Dan